U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula 3C6H11O7.Cr
Molecular Weight 637.4381
Optical Activity UNSPECIFIED
Defined Stereocenters 12 / 12
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CHROMIUM GLUCONATE

SMILES

[Cr+3].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O

InChI

InChIKey=ANPGUZATXCGJJH-OPDGVEILSA-K
InChI=1S/3C6H12O7.Cr/c3*7-1-2(8)3(9)4(10)5(11)6(12)13;/h3*2-5,7-11H,1H2,(H,12,13);/q;;;+3/p-3/t3*2-,3-,4+,5-;/m111./s1

HIDE SMILES / InChI

Molecular Formula C6H11O7
Molecular Weight 195.1473
Charge -1
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Molecular Formula Cr
Molecular Weight 51.9961
Charge 3
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Chromium sulfate(III) hexahydrate or chromium sulphate, a trivalent compound of chromium that was investigated as a toxic compound. Experiments on rodent have shown chromium sulfate produced severe and widespread effects in the nasal cavity, larynx, lungs, and mediastinal lymph node. Effects were characterized by the accumulation of foreign material, infiltration of alveolar macrophages, septal cell hyperplasia, and granulomatous and chronic inflammation. Besides, chromium sulphate exerted a disadvantageous effect on the skeleton, as it decreases bone density and resistance.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
CHROMIUM

Approved Use

Chromium 4 mcg/mL (Chromic Chloride Injection, USP) is indicated for use as a supplement to intravenous solutions given for total parenteral nutrition. Administration helps to maintain chromium serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms.

Launch Date

2005
PubMed

PubMed

TitleDatePubMed
Cytokine induction in human epidermal keratinocytes exposed to contact irritants and its relation to chemical-induced inflammation in mouse skin.
1994 Jun
Silicate antibodies in women with silicone breast implants: development of an assay for detection of humoral immunity.
1996 Mar
Activation of MAPKs in human bronchial epithelial cells exposed to metals.
1998 Sep
Thirteen-week subchronic rat inhalation toxicity study with a recovery phase of trivalent chromium compounds, chromic oxide, and basic chromium sulfate.
1999 Dec
Status of antioxidant defense system in chromium-induced Swiss mice tissues.
2004 Jul
The peripheral quantitative computed tomographic and densitometric analysis of skeletal tissue in male Wistar rats after chromium sulfate treatment.
2017 Sep 21
Patents

Patents

Substance Class Chemical
Created
by admin
on Mon Mar 31 21:32:30 GMT 2025
Edited
by admin
on Mon Mar 31 21:32:30 GMT 2025
Record UNII
V236ZVR3RL
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CHROMIUM GLUCONATE
Common Name English
CHROMIUM(III) GLUCONATE
Preferred Name English
D-GLUCONIC ACID, CHROMIUM SALT
Common Name English
Code System Code Type Description
DAILYMED
V236ZVR3RL
Created by admin on Mon Mar 31 21:32:30 GMT 2025 , Edited by admin on Mon Mar 31 21:32:30 GMT 2025
PRIMARY
RXCUI
1311292
Created by admin on Mon Mar 31 21:32:30 GMT 2025 , Edited by admin on Mon Mar 31 21:32:30 GMT 2025
PRIMARY RxNorm
PUBCHEM
71587119
Created by admin on Mon Mar 31 21:32:30 GMT 2025 , Edited by admin on Mon Mar 31 21:32:30 GMT 2025
PRIMARY
CAS
33661-40-4
Created by admin on Mon Mar 31 21:32:30 GMT 2025 , Edited by admin on Mon Mar 31 21:32:30 GMT 2025
PRIMARY
FDA UNII
V236ZVR3RL
Created by admin on Mon Mar 31 21:32:30 GMT 2025 , Edited by admin on Mon Mar 31 21:32:30 GMT 2025
PRIMARY
DRUG BANK
DB14528
Created by admin on Mon Mar 31 21:32:30 GMT 2025 , Edited by admin on Mon Mar 31 21:32:30 GMT 2025
PRIMARY
EPA CompTox
DTXSID20187342
Created by admin on Mon Mar 31 21:32:30 GMT 2025 , Edited by admin on Mon Mar 31 21:32:30 GMT 2025
PRIMARY
Related Record Type Details
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
PARENT -> SALT/SOLVATE
Related Record Type Details
ACTIVE MOIETY